Market View 28th December 2022

View on market: Stay Cautious, be with quality business:

Stocks in Asia fell Wednesday after US shares dropped and Treasury yields rose on growing unease that relaxing pandemic measures in China would add further inflation to the global economy. Stocks in Japan and Australia declined and South Korea’s Kospi benchmark tumbled as much as 2%. U.S. markets faltered as bond yields weighed on investor sentiment. The S&P 500 was little changed till mid-day, while the tech-heavy Nasdaq 100 fell 0.8%. The yield on 10-year Treasuries advanced nine basis points to 3.84%. Meanwhile, crude rose 1.7%, while gold futures increased 1.4%. Bitcoin declined 0.4% to trade around $16,800-level. Overseas investors in Indian equities remained net sellers for the third day in a row. Foreign portfolio investors offloaded equities worth Rs 867.6 crore, domestic investors, on the other hand, remained net buyers for the 15th day in a row and mopped up stocks worth Rs 621.8 crore, according to NSE data. India benchmark indices Sensex and Nifty continued their rally for a second day, paring losses from early trade to close higher at the end of a volatile day. Rupee reversed gains from a day before against the U.S. dollar amid month-end dollar demand among importers and forex outflows. At 6:42 a.m., the Singapore-traded SGX Nifty — an early barometer of India’s benchmark Nifty 50 — rose 0.38% to 18,079.5.

Economic Calendar:

• USD : Pending Home Sales (MoM) (Nov) on 28th December, 2022
• USD : Initial Jobless Claims on 29th December, 2022
• INR : Infrastructure Output (YoY) (Nov) on 30th December, 2022
• INR : Foreign Debt (USD) (Q3) on 30th December, 2022

Brokerage Radar:

MOSL ON AXIS BK: Buy, TP Rs 1130; Opex ratios to moderate; Improving granularity to drive sustainable RoE; Has multiple levers to offset rise in funding cost; Remains on track to deliver a sustainable RoE of 18% in medium term; Est. to deliver FY25 RoA/RoE of 1.8%/16.9%

NIRMAL BANG ON JUBILANT PHARMOVA: Buy TP Rs 432; Generic biz continues to face headwinds; In CDMO Sterile Injectables biz, management expects double-digit growth FY24 onwards, owing to strong order book position & capacity addition

KOTAK INST EQ ON INTERGLOBE: Buy, TP Rs 2400; Recent management meeting led us to recommend a BUY on extent of near-term improvement in profitability

Scope of market share loss over time—a risk that will impact INDIGO’s financials to a lesser extent

International Markets:

U.S & Europe

Asian markets

ADR Watch:

Commodities & Currency

FIIs & DIIs:

News Update:

Hindustan Petroleum Corporation: Amit Garg appointed as director (marketing) on the board of the company till March 31, 2027.

Punjab & Sind Bank: The board will meet on Dec. 30 to consider raising Rs 250 crore within 12 months.

Aditya Birla Capital: Sanchita Mustauphy appointed chief risk officer of the company, with effect from April 1, 2023, for five years.

Rail Vikas Nigam: The company has been appointed as the implementation agency for the UTF Harbor Project in Maldives, worth Rs 1,544.60 crore. This is a strategic project of the Government of India.

MOIL: Ajit Kumar Saxena has been appointed as chairman and managing director of the company till Dec. 31, 2025.

Suryoday Small Finance Bank: The RBI approved reappointment of Baskar Babu Ramachandran as the MD and CEO of the bank for three years, starting Jan. 23, 2023.

India Pesticides: The company’s subsidiary Shalvis Specialities has received environmental clearance for setting up manufacturing plant of agrochemicals and intermediates, API ingredients and intermediates and fine chemicals manufacturing unit in Hamirpur, Uttar Pradesh.

Source: Moneycontrol, Bloomberg Quint, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited, suhail@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL